Genetically engineered models have advantages over xenografts for preclinical studies Journal Article


Authors: Becher, O. J.; Holland, E. C.
Article Title: Genetically engineered models have advantages over xenografts for preclinical studies
Abstract: Mouse models of human cancer are valuable tools for cancer research. Although xenografts and genetically engineered models (GEMs) possess limitations as well as advantages, each system plays a significant role in preclinical testing. Tumor xenografts are easy to use, relatively inexpensive, and reproducible. The main drawback of xenografts is that the genetics and histology of the tumors are frequently not representative of the respective human tumor and, thus far, these models have not been as predictive of therapeutic success as one would like. By contrast, GEMs are histologically and genetically accurate models of human cancer but have disadvantages of heterogeneity with regard to frequency, latency, and growth. These disadvantages are reminiscent of the variable behavior of actual human tumors. Recently, these shortcomings have been partly overcome with the development of anatomic and molecular in vivo imaging techniques such as magnetic resonance imaging and bioluminescence imaging. These new technologies will hopefully support the use of GEMs in preclinical trials and help determine if trials in GEMs are more predicative than xenografts of human responses. ©2006 American Association for Cancer Research.
Keywords: review; nuclear magnetic resonance imaging; neoplasms; animals; mice; somatic cell; imatinib; platelet derived growth factor alpha receptor; stem cell factor; drug inhibition; metastasis; in vivo study; drug screening assays, antitumor; xenograft model antitumor assays; abelson kinase; chronic myeloid leukemia; cancer research; carcinogenesis; gene transfer; mice, transgenic; genetic engineering; xenograft; disease models, animal; bioluminescence
Journal Title: Cancer Research
Volume: 66
Issue: 7
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2006-04-01
Start Page: 3355
End Page: 3358
Language: English
DOI: 10.1158/0008-5472.can-05-3827
PUBMED: 16585152
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 54" - "Export Date: 4 June 2012" - "CODEN: CNREA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Eric Holland
    225 Holland
  2. Oren Josh Becher
    25 Becher